Unlocking Access to Cancer Care with Repurposed Generic Drugs and AI

Drug repurposing expands therapeutic possibilities by finding new uses for existing drugs. Dr. Laura Kleiman will discuss how repurposing generic drugs can rapidly create low-cost cancer treatments, sharing examples that provide accessible and affordable options for patients today while also driving new drug development. Her keynote presentation will highlight the tremendous opportunities in drug repurposing for cancer, addressing challenges such as regulatory hurdles, limited commercial incentives and the need for cross-sector collaboration.

Dr. Kleiman will describe Reboot Rx’s AI-driven approach and their prostate cancer project, which synthesized data from 16,000 studies and dozens of non-cancer generics already clinically evaluated for prostate cancer. She will share how this work identified top opportunities advancing toward clinical adoption and discuss Reboot Rx’s expanding pipeline across multiple cancer types. Dr. Kleiman will present a vision for a new regulatory pathway to accelerate adoption of repurposed generic drugs and expand access to life-saving treatments worldwide.

Bio

Dr. Laura Kleiman is the Founder and Chief Executive Officer of Reboot Rx, the nonprofit accelerating the development of affordable cancer treatments by repurposing generic drugs using their Artificial Intelligence (AI) technology. The Reboot Rx team — composed of experts in oncology drug development, AI, and policy — is redefining the standard of care for patients who need effective and accessible treatments now.

Prior to founding Reboot Rx, Dr. Kleiman was a Scientific Research Director at the Dana-Farber Cancer Institute. She earned a PhD in Computational and Systems Biology from Massachusetts Institute of Technology and completed an American Cancer Society Postdoctoral Fellowship at Massachusetts General Hospital and Harvard Medical School. Dr. Kleiman is a Draper Richards Kaplan Foundation Entrepreneur and Henri Termeer Fellow. Under Dr. Kleiman’s leadership, Reboot Rx’s groundbreaking work has attracted support from philanthropists; award recognition from several organizations; and features in Forbes, The Boston Globe, Inside Philanthropy and more.